NASDAQ: HARPHarpoon Therapeutics Inc Stock
$0.80+0.11 (+15.94%)
Updated Jun 2, 2023
HARP Price
$0.80
Fair Value Price
$2.36
Market Cap
$30.08M
52 Week Low
$0.54
52 Week High
$3.36
P/E
-0.46x
P/B
42.07x
P/S
0.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.59M
Earnings
-$58.75M
Gross Margin
100%
Operating Margin
-169.43%
Profit Margin
-169.8%
Debt to Equity
112.02
Operating Cash Flow
-$83M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HARP Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HARP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HARP ($0.80) is undervalued by 66.05% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HARP ($0.80) is significantly undervalued by 66.05% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HARP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HARP due diligence checks available for Premium users.
Be the first to know about important HARP news, forecast changes, insider trades & much more!
HARP News
Valuation
HARP fair value
Fair Value of HARP stock based on Discounted Cash Flow (DCF)
Price
$0.80
Fair Value
$2.36
Undervalued by
66.05%
HARP ($0.80) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HARP ($0.80) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HARP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HARP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.46x
Industry
11.51x
Market
52.74x
HARP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
42.07x
Industry
5.19x
HARP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HARP's financial health
Profit margin
Revenue
$8.6M
Net Income
-$11.3M
Profit Margin
-132.1%
HARP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HARP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$80.8M
Liabilities
$80.1M
Debt to equity
112.02
HARP's short-term assets ($63.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HARP's short-term assets ($63.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HARP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
$2.4M
Financing
$26.6M
HARP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HARP vs Biotech Stocks
Harpoon Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.